Added to YB: 2026-03-16
Pitch date: 2026-03-12
GSK [neutral]
GSK plc
+0.1%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 82.7B
Pitch Price
GBP 20.29
Price Target
N/A
Dividend
3.48%
EV/EBITDA
8.38
P/E
14.88
EV/Sales
2.96
Sector
Pharmaceuticals
Category
special_situation
Theodosian Capital | Stocks Update 12/3/2026 - GSK – Monetisation
GSK (update): Sold linerixibat (IBAT inhibitor) rights to Alfasigma for $300M upfront + $100M on FDA approval (expected this month) + $20M UK/EU approval + up to $270M sales milestones + double-digit royalties. Smart non-core asset sale. Trades 10.4x 2027 EPS, 3.7% yield.
Read full article (1 min)